IOMX
LIVE

Serial Number

79419666

Owner

iOmx Therapeutics AG

Attorney

Alisa C. Simmons

Filing Date

Dec 18, 2024

Add to watchlist:

No watchlists yet
View on USPTO

IOMX Trademark

Serial Number: 79419666

IOMX is a trademark filed by iOmx Therapeutics AG on December 18, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

iOmx Therapeutics AG

Fraunhofer Str. 22

Entity Type: 99

Trademark Details

Filing Date

December 18, 2024

Registration Date

Not Registered

Goods & Services

Pharmaceutical diagnostic medical and veterinary preparations; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of diseases, ailments and disorders in humans and animals, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, ailments and disorders and the treatment and prevention of complications associated with such diseases, ailments and disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of illnesses, ailments and disorders in humans and animals, in particular bone, sensory organ, viral, urinary tract, kidney, metabolic and central nervous system diseases, complaints and disorders and the treatment or prevention of complications associated with such diseases, ailments and disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or and prevention of diseases, ailments and disorders in humans and animals, in particular infectious, autoimmune or and immunological, cell proliferative and oncological diseases, ailments and disorders, cancers, tumours and metastases and the treatment and prevention of complications associated with such diseases, ailments and disorders; pharmaceutical preparations and formulations and medical health preparations, in particular artificial polypeptides and proteins, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding for these, in particular for use in the following areas: treatment and prevention of various types of cancer, inflammatory diseases and autoimmune diseases; diagnostic preparations and biomarker reagents for medical and veterinary purposes; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and prognosis of human and animal diseases, ailments and disorders, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or and gastrointestinal diseases, ailments and disorders and the diagnosis and prognosis in relation to complications associated with such diseases, ailments and disorders; diagnostic preparations and diagnostic biomarker reagents for medical purposes, namely, for the diagnosis and prognosis of human and animal diseases, ailments and disorders, in particular bone, sensory organ, virus, urinary tract, kidney, metabolic and central nervous system diseases, ailments and disorders and the diagnosis and prognosis in relation to complications associated with such diseases, ailments and disorders; diagnostic preparations and diagnostic biomarker reagents for medical purposes, namely, for the diagnosis and prognosis of diseases, ailments and disorders in humans and animals, in particular infectious, autoimmune and immunological, cell proliferative and oncological diseases, ailments and disorders, cancers, tumours and metastases and the diagnosis and prognosis in relation to complications associated with such diseases, ailments and disorders.

Chemical preparations for scientific and general industrial manufacturing purposes; Biochemical preparations, namely, genetically engineered polypeptides, for scientific purposes and proteins in raw material form for scientific and medical research, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding sequences for these for scientific purposes, in particular artificial polypeptides and proteins and nucleic acid coding sequences for these for scientific purposes; diagnostic preparations, except for medical or veterinary use.

Scientific services, namely, scientific research in the field of biology, chemistry or medicine, as well as immunology, oncology, molecular biology, cell biology, biochemistry and medicinal chemistry, and relating to the discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic agents and diagnostic biomarker reagents and diagnostic apparatus; conducting early evaluations in the field of new pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of platform technology, namely a cancer immunotherapy platform for the production of therapeutics; chemical, biological and biochemical laboratory services; conducting chemical, biochemical and biological analyses; Medical and scientific research in the field of cancer diagnostics for scientific purposes; Biological and biochemical research laboratory services; Forensic pathological biological and biochemical examination services; providing technical and scientific research information in the field of biotechnology about a biotechnology company, its technologies, projects, product candidates, products and services via a web site on a global computer network; software design and development; design and development of computer software for use in the fields of biology, chemistry or medicine, in particular immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry, as well as in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents and diagnostic apparatus.

Filing History

NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 16, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jun 16, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jun 16, 2026 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
May 26, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 26, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 26, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 27, 2026 GNRN
NON-FINAL ACTION E-MAILED
Feb 27, 2026 GNRT
NON-FINAL ACTION WRITTEN
Feb 27, 2026 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 27, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 27, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 27, 2026 TROA
REFUSAL PROCESSED BY IB
Aug 15, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 29, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jul 29, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 8, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jun 6, 2025 CNRT
ASSIGNED TO EXAMINER
Jun 4, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 21, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 21, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 20, 2025 REPR